1887

Abstract

The move towards pathology networks and hub-and-spoke models of medical laboratory service provision has significantly changed the flow of samples, and the impact of results on patients, over recent years. At the same time advances in technology, including rapid, simple to use molecular platforms, are changing the way microbiology results can be utilized. Like many other medical microbiology laboratories, we struggle with this balance for many different sample types and test requests. Work published by Neilson et al. in Journal of Medical Microbiology last year looked at this balance for methicillin-resistant Staphylococcus aureus (MRSA) genotypic diagnostics and suggested significant cost savings when a whole-healthcare economy perspective was adopted. However, as with all changes, implementing MRSA molecular diagnostics in different clinical settings must be considered carefully. We add to this discussion in our accompanying letter, detailing our experience (in a hub-and-spoke medical microbiology laboratory setting) of ‘rapid’ MRSA molecular diagnostics for day-case surgery where pre-operative assessment had been missed, exploring the impact and costs of these tests. We find no impact on patient care, but at considerable additional cost. We hope this will add a cautionary note to those considering implementing molecular microbiology diagnostics, and reopen the debate on where, in hub-and-spoke laboratory models, such devices should be situated.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000919
2019-01-10
2020-01-23
Loading full text...

Full text loading...

/deliver/fulltext/jmm/68/3/290.html?itemId=/content/journal/jmm/10.1099/jmm.0.000919&mimeType=html&fmt=ahah

References

  1. Nielsen XC, Madsen TV, Engberg J. Evaluation of Xpert MRSA Gen 3 and BD MAX MRSA XT for meticillin-resistant Staphylococcus aureus screening in a routine diagnostic setting in a low-prevalence area. J Med Microbiol 2017;66:90–95 [CrossRef][PubMed]
    [Google Scholar]
  2. National Institute for Health and Care Excellence NICE support for commissioning for surgical site infection. Quality Standard 2013;49: Available fromhttps://www.nice.org.uk/guidance/qs49/resources [Accessed 10 Dec 2018]
    [Google Scholar]
  3. Jenks PJ, Laurent M, Mcquarry S, Watkins R. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect 2014;86:24–33 [CrossRef][PubMed]
    [Google Scholar]
  4. Anderson DJ, Kaye KS, Chen LF, Schmader KE, Choi Y et al. Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study. PLoS One 2009;4:e8305 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000919
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error